NVCR logo

NovoCure Limited (NVCR) EBITDA

Annual EBITDA:

-$109.58M+$67.87M(+38.25%)
December 31, 2024

Summary

  • As of today, NVCR annual EBITDA is -$109.58 million, with the most recent change of +$67.87 million (+38.25%) on December 31, 2024.
  • During the last 3 years, NVCR annual EBITDA has fallen by -$71.20 million (-185.49%).
  • NVCR annual EBITDA is now -344.42% below its all-time high of $44.83 million, reached on December 31, 2020.

Performance

NVCR EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVCRincome statement metrics

Quarterly EBITDA:

-$32.36M+$3.72M(+10.31%)
September 30, 2025

Summary

  • As of today, NVCR quarterly EBITDA is -$32.36 million, with the most recent change of +$3.72 million (+10.31%) on September 30, 2025.
  • Over the past year, NVCR quarterly EBITDA has dropped by -$2.72 million (-9.19%).
  • NVCR quarterly EBITDA is now -288.02% below its all-time high of $17.21 million, reached on September 30, 2020.

Performance

NVCR Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVCRincome statement metrics

TTM EBITDA:

-$162.22M-$2.72M(-1.71%)
September 30, 2025

Summary

  • As of today, NVCR TTM EBITDA is -$162.22 million, with the most recent change of -$2.72 million (-1.71%) on September 30, 2025.
  • Over the past year, NVCR TTM EBITDA has dropped by -$22.89 million (-16.42%).
  • NVCR TTM EBITDA is now -474.42% below its all-time high of $43.33 million, reached on March 31, 2021.

Performance

NVCR TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherNVCRincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

NVCR EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+38.3%-9.2%-16.4%
3Y3 Years-185.5%-47.4%-173.3%
5Y5 Years-911.1%-288.0%-687.6%

NVCR EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-185.5%+38.3%-47.4%+46.0%-173.3%+24.6%
5Y5-Year-344.4%+38.3%-288.0%+46.0%-474.4%+24.6%
All-TimeAll-Time-344.4%+38.3%-288.0%+46.0%-474.4%+24.6%

NVCR EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$32.36M(+10.3%)
-$162.22M(-1.7%)
Jun 2025
-
-$36.08M(-4.4%)
-$159.50M(-3.5%)
Mar 2025
-
-$34.54M(+41.7%)
-$154.17M(+1.4%)
Dec 2024
-$109.58M(+38.2%)
-$59.25M(-99.9%)
-$156.30M(-12.2%)
Sep 2024
-
-$29.63M(+3.6%)
-$139.34M(+15.6%)
Jun 2024
-
-$30.75M(+16.2%)
-$165.14M(+15.0%)
Mar 2024
-
-$36.67M(+13.3%)
-$194.33M(+9.7%)
Dec 2023
-$177.45M(-161.4%)
-$42.28M(+23.7%)
-$215.19M(-0.9%)
Sep 2023
-
-$55.44M(+7.5%)
-$213.19M(-18.6%)
Jun 2023
-
-$59.94M(-4.2%)
-$179.70M(-30.0%)
Mar 2023
-
-$57.53M(-42.8%)
-$138.23M(-75.2%)
Dec 2022
-$67.89M(-76.9%)
-$40.28M(-83.5%)
-$78.90M(-32.9%)
Sep 2022
-
-$21.95M(-18.8%)
-$59.35M(-37.3%)
Jun 2022
-
-$18.47M(-1124.1%)
-$43.22M(-25.1%)
Mar 2022
-
$1.80M(+108.7%)
-$34.56M(-1.4%)
Dec 2021
-$38.38M(-185.6%)
-$20.73M(-256.3%)
-$34.08M(-2907.4%)
Sep 2021
-
-$5.82M(+40.7%)
$1.21M(-95.0%)
Jun 2021
-
-$9.81M(-530.1%)
$24.24M(-44.0%)
Mar 2021
-
$2.28M(-84.3%)
$43.33M(+9.5%)
Dec 2020
$44.83M(+231.9%)
$14.56M(-15.4%)
$39.55M(+43.3%)
Sep 2020
-
$17.21M(+85.7%)
$27.61M(+70.6%)
Jun 2020
-
$9.27M(+720.8%)
$16.18M(+58.0%)
Mar 2020
-
-$1.49M(-157.0%)
$10.24M(+35.7%)
DateAnnualQuarterlyTTM
Dec 2019
$13.51M(+165.4%)
$2.62M(-54.7%)
$7.54M(+592.2%)
Sep 2019
-
$5.79M(+73.9%)
-$1.53M(+85.1%)
Jun 2019
-
$3.33M(+179.4%)
-$10.26M(+44.2%)
Mar 2019
-
-$4.19M(+35.1%)
-$18.38M(+25.5%)
Dec 2018
-$20.67M(+32.4%)
-$6.46M(-120.1%)
-$24.67M(-20.0%)
Sep 2018
-
-$2.94M(+38.8%)
-$20.56M(+4.3%)
Jun 2018
-
-$4.80M(+54.2%)
-$21.49M(+29.3%)
Mar 2018
-
-$10.47M(-345.1%)
-$30.41M(+3.9%)
Dec 2017
-$30.56M(+72.2%)
-$2.35M(+39.1%)
-$31.65M(+30.6%)
Sep 2017
-
-$3.87M(+71.8%)
-$45.59M(+33.4%)
Jun 2017
-
-$13.72M(-17.1%)
-$68.43M(+18.7%)
Mar 2017
-
-$11.71M(+28.1%)
-$84.13M(+18.5%)
Dec 2016
-$109.88M(-8.1%)
-$16.29M(+39.0%)
-$103.25M(+11.3%)
Sep 2016
-
-$26.71M(+9.2%)
-$116.42M(-3.0%)
Jun 2016
-
-$29.42M(+4.6%)
-$113.05M(-2.5%)
Mar 2016
-
-$30.84M(-4.7%)
-$110.25M(-9.4%)
Dec 2015
-$101.62M(-29.8%)
-$29.45M(-26.2%)
-$100.81M(-41.3%)
Sep 2015
-
-$23.34M(+12.3%)
-$71.35M(-48.6%)
Jun 2015
-
-$26.62M(-24.4%)
-$48.01M(-13.9%)
Mar 2015
-
-$21.39M(-3.1%)
-$42.14M(-10.1%)
Dec 2014
-$78.30M(-14.1%)
-
-
Jun 2014
-
-$20.75M(-18.3%)
-$38.29M(-118.3%)
Mar 2014
-
-$17.54M
-$17.54M
Dec 2013
-$68.64M
-
-

FAQ

  • What is NovoCure Limited annual EBITDA?
  • What is the all-time high annual EBITDA for NovoCure Limited?
  • What is NovoCure Limited annual EBITDA year-on-year change?
  • What is NovoCure Limited quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for NovoCure Limited?
  • What is NovoCure Limited quarterly EBITDA year-on-year change?
  • What is NovoCure Limited TTM EBITDA?
  • What is the all-time high TTM EBITDA for NovoCure Limited?
  • What is NovoCure Limited TTM EBITDA year-on-year change?

What is NovoCure Limited annual EBITDA?

The current annual EBITDA of NVCR is -$109.58M

What is the all-time high annual EBITDA for NovoCure Limited?

NovoCure Limited all-time high annual EBITDA is $44.83M

What is NovoCure Limited annual EBITDA year-on-year change?

Over the past year, NVCR annual EBITDA has changed by +$67.87M (+38.25%)

What is NovoCure Limited quarterly EBITDA?

The current quarterly EBITDA of NVCR is -$32.36M

What is the all-time high quarterly EBITDA for NovoCure Limited?

NovoCure Limited all-time high quarterly EBITDA is $17.21M

What is NovoCure Limited quarterly EBITDA year-on-year change?

Over the past year, NVCR quarterly EBITDA has changed by -$2.72M (-9.19%)

What is NovoCure Limited TTM EBITDA?

The current TTM EBITDA of NVCR is -$162.22M

What is the all-time high TTM EBITDA for NovoCure Limited?

NovoCure Limited all-time high TTM EBITDA is $43.33M

What is NovoCure Limited TTM EBITDA year-on-year change?

Over the past year, NVCR TTM EBITDA has changed by -$22.89M (-16.42%)
On this page